Justin Kromelow, CEO & founder of OPOSPrior to delivering any products or services, OPOS performs a regulatory compliance risk analysis for its customers at no cost.
The company evaluates a substantial amount of clinical data related to opioid and controlled substance prescriptions.Following which, the team analyzes the data across compliance criteria to evaluate and quantify the risk for each criterion.
As OPOS traverses into the future, it plans to productize its service for risk assessment into a standalone product for physicians, practices, and organizations to streamline their regulatory compliance program efficiently. The standalone product will enable real-time regulatory monitoring, providing customers with information on issues related to prescribing opioids and controlled substances in compliance with the regulatory environment through a real-time dashboard. OPOS is also looking forward to introducing new digital therapeutics with an integrated regulatory compliance framework that will allow clients to assess practices, tools, and platforms from a regulatory perspective and be compliant; at the same time they are working to maximize clinical outcomes for patients.
What differentiates OPOS’ solution is the historical perspective applied to a customer’s regulatory compliance strategy and risk mitigation plans. OPOS performs the compliance risk assessment considering several years of data and not simply the current scenario, which benefits physicians by showing them how the regulatory agencies and medical boards view their opioid and controlled substance prescribing compliance. Additionally, OPOS works with its clients to assess underlying clinical and administrative process to ensure comprehensive risk containment.
OPOS has helped many physicians that have received medical board accusations of non-compliance and non-adherence to opioid prescribing regulatory requirements as well as physicians looking for ways to reduce the cost and overhead of regulatory compliance. OPOS’ offerings enable both groups to successfully demonstrate regulatory compliance in a profitable manner, winning the confidence of clients. This unique approach taken by OPOS enables their clients to be able to offset large compliance costs, typically hundreds of thousands of dollars, with new revenue.
OPOS plans to productize its service for risk assessment into a standalone product for doctors, physicians, practices, and organizations to efficiently streamline their regulatory compliance program in a profitable manner
As OPOS traverses into the future, it plans to productize its service for risk assessment into a standalone product for physicians, practices, and organizations to streamline their regulatory compliance program efficiently. The standalone product will enable real-time regulatory monitoring, providing customers with information on issues related to prescribing opioids and controlled substances in compliance with the regulatory environment through a real-time dashboard. OPOS is also looking forward to introducing new digital therapeutics with an integrated regulatory compliance framework that will allow clients to assess practices, tools, and platforms from a regulatory perspective and be compliant; at the same time they are working to maximize clinical outcomes for patients.
Regulatory Services for Chronic Opioid Therapy Require Clinical Proof
Life science executives evaluating regulatory service providers are operating in an environment defined by heightened scrutiny, compressed clinical timelines, and growing tension between patient access and accountability. In the context of chronic opioid therapy, the challenge extends far beyond documentation alone. Must document how the order relates to a defensible plan of care, active assessment of the patient's risk and evidence of the ongoing benefit from the therapy being provided. In visit-based care settings, this is often a challenge. Clinicians often have only limited time to review a patient’s prior month, assess evolving risk, answer questions, and generate records capable of withstanding scrutiny from medical boards, federal agencies, payers, or regulators.
The strongest regulatory service providers, therefore, cannot operate as simple paperwork vendors. They will assist healthcare organizations in creating actionable evidence during the delivery of care. This means collecting patient input between visits for chronic pain management, turning the input into actionable prescriber prompts and having risk identified prior to a failure in the clinic or in compliance. Retrospective chart audits or post-hoc chart remediation will do nothing to fix the operational problem-clinicians still do not have a way to access relevant patient information at the point the decision to prescribe is made. Successful partners must also have substantial subject matter expertise because regulations around prescribing opioids aren't abstract policy exercises. These regulations impact patient access, provider licensure, patient continuity, and the burden on providers making real-time clinical decisions under pressure.
Compliance and patient function are related equally to medication efficacy and safety. Opioid therapy can become ineffective with escalating tolerance, and the side effects of increasing dosage are often safety and addiction concerns. A good regulatory partner should be able to assist the physician in identifying the minimum effective dosage of a particular medication that will achieve independence, day-to-day functioning and quality of life. This reframes compliance from a defensive administrative exercise into a more disciplined model of care management, where monitoring, risk stratification, education, and documentation all support the same clinical objective. It also provides an easier way for leadership teams to assess value: the service should decrease preventable risk while also enabling patients to communicate more effectively, participate more vigorously in their treatment, and progress towards safer alternatives.
Scalability matters as well. Regulatory support must align with the economics and operational realities of specialty pain and primary care practices rather than adding another layer of uncompensated administrative burden. Though the patient population differs greatly, the vast majority of organizations are looking for some sort of structured way to tier less-risk patients that require standard follow-up from the higher-risk patients that are receiving more intense touch and more review and analysis. The most robust models give back time, not take up clinician time. These assist practices in proving compliance, keeping pace with evolving regulations and concentrating attention where patient risk is highest. Equally critically, they provide management with the ability to determine whether the compliance effort is improving access to care, reducing remaining risk, and enhancing the clinical foundation of the prescriber.
In this health environment, with integration between compliance, the outcome, and access, the effective regulatory service is an organization that links the evidence gathering process to the patients' care, not an administrative process itself.
This system features OPOS, an excellent option for an organization overseeing patients on chronic opioid therapy, as the integrated system includes OPOS Foresight and OPOS Telepain.MD, and OPOS Insight for compliance documentation, patient education, psychometric testing, risk-based monitoring and clinical decision support. The model incorporates telemedicine education, patient-generated data, and both group and individual care formats to help prescribers address expectations from medical boards, the CDC, and the DEA while expanding access to pain management expertise. OPOS is well-equipped to partner with Pain Specialty and Primary Care practices that are seeking additional reassurance on compliance issues without separating the responsibility for managing compliance from patient results.
...Read more
